HK1197035A1 - Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof - Google Patents

Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof Download PDF

Info

Publication number
HK1197035A1
HK1197035A1 HK14110576.5A HK14110576A HK1197035A1 HK 1197035 A1 HK1197035 A1 HK 1197035A1 HK 14110576 A HK14110576 A HK 14110576A HK 1197035 A1 HK1197035 A1 HK 1197035A1
Authority
HK
Hong Kong
Prior art keywords
composition
release component
metabolite
doxylamine
pyridoxine
Prior art date
Application number
HK14110576.5A
Other languages
English (en)
Chinese (zh)
Inventor
Manon VRANDERICK
Jean-Luc ST-ONGE
Christelle GEDEON
Michele Gallo
Éric GERVAIS
Original Assignee
Duchesnay Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49004884&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1197035(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Duchesnay Inc. filed Critical Duchesnay Inc.
Publication of HK1197035A1 publication Critical patent/HK1197035A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK14110576.5A 2012-02-22 2013-02-18 Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof HK1197035A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261601754P 2012-02-22 2012-02-22
US61/601,754 2012-02-22
PCT/CA2013/050125 WO2013123595A1 (en) 2012-02-22 2013-02-18 Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
HK18107138.8A Division HK1247571B (en) 2012-02-22 2014-10-23 Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
HK18107138.8A Addition HK1247571B (en) 2012-02-22 2014-10-23 Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof

Publications (1)

Publication Number Publication Date
HK1197035A1 true HK1197035A1 (en) 2015-01-02

Family

ID=49004884

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14110576.5A HK1197035A1 (en) 2012-02-22 2013-02-18 Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof

Country Status (25)

Country Link
US (3) US9089489B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP3326611B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JP5914701B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR101588259B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN104136004B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (2) AR090126A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2013224598B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112014020186A8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2848798C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CL (1) CL2014001828A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (1) CY1123122T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK3326611T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2809713T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK1197035A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUE052301T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL233644A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (1) LT3326611T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX355912B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ627593A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL3326611T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT3326611T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG11201403931YA (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI638657B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UY (1) UY34631A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2013123595A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1197035A1 (en) 2012-02-22 2015-01-02 Duchesnay Inc. Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
US9452181B2 (en) 2013-07-22 2016-09-27 Duchesnay Inc. Composition for the management of nausea and vomiting
HUE039131T2 (hu) 2013-07-22 2018-12-28 Duchesnay Inc Hányinger és hányás kezelésére szolgáló készítmény
CN103432126A (zh) * 2013-08-05 2013-12-11 北京阜康仁生物制药科技有限公司 一种治疗孕吐的药物组合物
EP3185856B1 (en) * 2014-08-29 2018-05-23 Duchesnay Inc. Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
WO2017029573A1 (en) 2015-08-17 2017-02-23 Aequus Pharmaceuticals Inc. Transdermal delivery of doxylamine succinate and pyridoxine hydrochloride
EP3697392B1 (en) 2017-10-17 2023-11-15 Synthon B.V. Tablets comprising tamsulosin and solifenacin
HUE053082T2 (hu) * 2018-09-27 2021-06-28 Inibsa Ginecologia S A Eljárás doxilamin-szukcinát- és piridoxin-hidroklorid-tartalmú, módosított hatóanyag-leadású, több kis egységet tartalmazó, orális adagolási forma elõállítására
AR121619A1 (es) * 2020-03-25 2022-06-22 Inibsa Ginecologia S A Una forma de dosificación oral de múltiples unidades de liberación modificada de succinato de doxilamina y clorhidrato de piridoxina y un procedimiento para su preparación
WO2022254277A1 (en) * 2021-05-31 2022-12-08 Maneesh Pharmaceuticals Ltd Extended release composition and its process for the preparation
AU2021225255B1 (en) * 2021-09-03 2022-06-16 Patel, Mihir MR Compositions, kits, and methods to provide synergistic and/or additive effects from comprised ingredients for the prevention, treatment and management of nausea and vomiting.
WO2024180559A1 (en) * 2023-03-01 2024-09-06 Akums Drugs & Pharmaceuticals Limited A stable tablet-in-tablet composition for nausea vomiting in pregnancy

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8518301D0 (en) 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
GB8524001D0 (en) 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
US4842867A (en) 1986-05-09 1989-06-27 Alza Corporation Pulsed drug delivery of doxylamine
IT1201136B (it) 1987-01-13 1989-01-27 Resa Farma Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive
US5110597A (en) 1987-06-25 1992-05-05 Alza Corporation Multi-unit delivery system
US5017381A (en) 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
US5387421A (en) 1991-01-31 1995-02-07 Tsrl, Inc. Multi stage drug delivery system
NZ242065A (en) 1991-03-26 1996-06-25 Csl Ltd Delayed release implant having a degradable or rupturable polymeric coating
US5260068A (en) 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
DE19716732C2 (de) 1997-03-07 1999-03-25 Max Delbrueck Centrum Spezifische Magnetosomen, Verfahren zu ihrer Herstellung und ihre Verwendung
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US7744916B2 (en) 1997-06-11 2010-06-29 Umd, Inc. Coated vaginal device for delivery of anti-migraine and anti-nausea drugs
FR2772615B1 (fr) 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
US6531152B1 (en) 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
EP1191924A4 (en) 1999-04-06 2005-02-09 Pharmaquest Ltd PHARMACEUTICAL DOSAGE FORM FOR INTERMITTENT ADMINISTRATION OF (D-THREO) -METHYLPHENIDATE AND A SECOND STIMULANT OF THE CENTRAL NERVOUS SYSTEM
US6197329B1 (en) 1999-05-03 2001-03-06 Drugtech Corporation Anti-nausea compositions and methods
US6632451B2 (en) 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
WO2001037721A2 (en) 1999-11-22 2001-05-31 The Research Foundation Of State University Of New York Magnetic nanoparticles for selective therapy
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6500457B1 (en) 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
US6924273B2 (en) 2000-10-03 2005-08-02 Scott W. Pierce Chondroprotective/restorative compositions and methods of use thereof
CA2350195C (en) 2000-12-20 2003-06-10 Duchesnay Inc. Rapid onset formulation of pyridoxine hydrochloride and doxylamine succinate
US6976982B2 (en) 2001-01-09 2005-12-20 Microchips, Inc. Flexible microchip devices for ophthalmic and other applications
US6997863B2 (en) 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
US7704542B2 (en) 2001-09-12 2010-04-27 Xanodyne Pharmaceuticals, Inc. Vitamin/mineral compositions with DHA
CA2392486A1 (en) 2002-07-05 2002-12-08 Duchesnay Inc. Pharmaceutical dosage form bearing pregnancy-friendly indicia
ATE505224T1 (de) 2002-08-16 2011-04-15 Microchips Inc Vorrichtung mit kontrollierter abgabe und verfahren
GB0229725D0 (en) 2002-12-19 2003-01-29 Univ Wales Medicine Haplotype partitioning and growth hormone SNPs
ATE424928T1 (de) 2004-09-01 2009-03-15 Microchips Inc Behältervorrichtungen mit mehreren verschlüssen zur gesteuerten abgabe oder exponierung des behälterinhalts
GB0502475D0 (en) * 2005-02-07 2005-03-16 Sb Pharmco Inc Novel compositions
US20070141147A1 (en) * 2005-12-21 2007-06-21 Auriga Laboratories, Inc. Sequential release pharmaceutical formulations
US9034843B2 (en) 2007-09-14 2015-05-19 Rohto Pharmaceutical Co., Ltd. Ophthalmic composition
KR101190708B1 (ko) * 2010-03-12 2012-10-12 주식회사 대웅제약 모사프리드 또는 이의 염을 포함하는 서방형 약학 조성물
AU2011236548A1 (en) * 2010-04-07 2012-11-01 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
MX2012015188A (es) * 2010-06-22 2013-05-20 Twi Pharmaceuticals Inc Composiciones de liberacion controlada con efecto de alimentos reducido.
WO2013123569A1 (en) 2012-02-22 2013-08-29 Duchesnay Inc. Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
HK1197035A1 (en) 2012-02-22 2015-01-02 Duchesnay Inc. Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
US9452181B2 (en) 2013-07-22 2016-09-27 Duchesnay Inc. Composition for the management of nausea and vomiting

Also Published As

Publication number Publication date
US20150366808A1 (en) 2015-12-24
JP5914701B2 (ja) 2016-05-11
BR112014020186A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2017-06-20
AR122580A2 (es) 2022-09-21
HUE052301T2 (hu) 2021-04-28
CY1123122T1 (el) 2021-10-29
UY34631A (es) 2013-09-30
AU2013224598A1 (en) 2014-07-31
SG11201403931YA (en) 2014-08-28
EP2787971A1 (en) 2014-10-15
ES2809713T3 (es) 2021-03-05
PT3326611T (pt) 2020-08-20
EP3326611A1 (en) 2018-05-30
CA2848798C (en) 2014-12-23
JP2016053092A (ja) 2016-04-14
CN104136004A (zh) 2014-11-05
CA2848798A1 (en) 2013-08-29
KR20140139496A (ko) 2014-12-05
US9089489B2 (en) 2015-07-28
WO2013123595A1 (en) 2013-08-29
MX2014008594A (es) 2015-03-03
TWI638657B (zh) 2018-10-21
CL2014001828A1 (es) 2014-11-14
AR090126A1 (es) 2014-10-22
IL233644A (en) 2016-05-31
US9375404B2 (en) 2016-06-28
US20160374946A1 (en) 2016-12-29
TW201334780A (zh) 2013-09-01
DK3326611T3 (da) 2020-08-17
US9937132B2 (en) 2018-04-10
CN104136004B (zh) 2018-03-06
MX355912B (es) 2018-05-04
EP2787971A4 (en) 2015-04-29
AU2013224598B2 (en) 2015-09-17
NZ627593A (en) 2015-12-24
PL3326611T3 (pl) 2020-11-02
IL233644A0 (en) 2014-08-31
EP3326611B1 (en) 2020-05-06
KR101588259B1 (ko) 2016-01-25
LT3326611T (lt) 2020-08-25
US20140314680A1 (en) 2014-10-23
BR112014020186A8 (pt) 2017-07-11
JP2015508082A (ja) 2015-03-16

Similar Documents

Publication Publication Date Title
HK1197035A1 (en) Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
EP3040072A4 (en) Pharmaceutical composition having pyrimidine compound as active ingredient
EP2522653A4 (en) BIGUANIDE DERIVATIVE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE BIGUANIDE DERIVATIVE AS AN ACTIVE SUBSTANCE
WO2011120904A3 (en) A fast dissolving pharmaceutical composition
HUE037742T2 (hu) Szubsztituált azolok, vírusellenes aktív adalék, gyógyszerészeti készítmény, az elõállításukat célzó eljárás és alkalmazásuk
HK1213779A1 (zh) 用於立即和延长释放的组合物
WO2011104652A3 (en) Veterinary compositions
WO2012085927A3 (en) Tadalafil compositions
WO2011120903A3 (en) A fast dissolving pharmaceutical composition
MX2016003754A (es) Una composicion farmaceutica estable que contiene amlodipina y valsartan.
WO2012158030A3 (en) Drug delivery system
PL2865664T3 (pl) Nowy związek mający zdolność hamowania enzymu 11ß-HSD1, lub jego farmaceutycznie dopuszczalna sól, sposób wytwarzania go, i kompozycja farmaceutyczna zawierająca go jako składnik aktywny
WO2011152652A3 (ko) 1일 1회 투여로 최적의 약리학적 임상 효과를 제공하는 아세클로페낙 서방성 제제
WO2012029074A3 (en) Pharmaceutical compositions of linezolid
WO2012014052A3 (en) Novel coated extended release pharmaceutical compositions containing paliperidone
SA517380942B1 (ar) صيغة إطلاق متعددة النماذج للدوكسيلامين والبيريدوكسين و/أو نواتج أيض أو أملاح منها
WO2012006566A3 (en) Microcrystalline y receptor agonists
WO2011107921A3 (en) Modified release composition of milnacipran
WO2009121946A3 (en) Process for the preparation of optically enriched clopidogrel
TW201613584A (en) Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
WO2012111961A3 (ko) 티아넵틴 또는 이의 약제학적으로 허용되는 염을 포함하는 경구투여용 서방성 정제
WO2013072770A3 (en) Pharmaceutical formulations comprising atorvastatin and glimepiride
WO2013054364A3 (en) Novel salts of sitagliptin, process for the preparation and pharmaceutical composition thereof
MX2016000884A (es) Composicion para la gestion de las nauseas y los vomitos.
WO2013095042A3 (ko) 이매티닙메실산염 함유 과립, 이를 포함하는 경구용 속방성 정제 조성물 및 그것의 제조방법